Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis

Antimicrob Agents Chemother. 2019 Apr 25;63(5):e02569-18. doi: 10.1128/AAC.02569-18. Print 2019 May.

Abstract

Levofloxacin is used to treat and prevent drug-resistant tuberculosis in children. We assessed levofloxacin serum drug concentrations in 24 children aged 2 to 10 years who received levofloxacin-based tuberculosis preventive therapy in Karachi, Pakistan. Only 9 children (37.5%) achieved adequate drug exposure. Target serum drug concentration was met in 4 (26.7%) of 15 children dosed consistently with World Health Organization recommendations and 4 (80.0%) of 5 who received higher-than-recommended doses. Levofloxacin dosing recommendations may require reevaluation.

Keywords: Pakistan; children; fluoroquinolones; multidrug-resistant tuberculosis; pharmacokinetics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use
  • Humans
  • Levofloxacin / pharmacology*
  • Levofloxacin / therapeutic use*
  • Microbial Sensitivity Tests
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / pathogenicity
  • Pakistan
  • Tuberculosis, Multidrug-Resistant / drug therapy
  • Tuberculosis, Multidrug-Resistant / microbiology

Substances

  • Antitubercular Agents
  • Levofloxacin